BALCAO · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · SMALL CAP
Cosciens Biopharma Inc. CSCID
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.5M
▼ 21.8% vs FY2024
EPS · FY25
$-3.27
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-121.8%
Net margin · FY25
-138.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.5M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 138 cents on every revenue dollar this year.
Per share
USD -3.27
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-121.8%
Return on equity, FY2025
ROE
Operating margin-142.5%
Net margin-138.1%
Return on assets-36.7%
Each USD of equity lost 122 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+15.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−19.9%
+15.5%
+30.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 21.4M
total assets, end of FY2025
Total assetsUSD 21.4M
EquityUSD 3.8M
CashUSD 7.3M
Current ratio3.18×
Equity funds 18% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
·
0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.1
EPS, diluted $
−3.27
−5.93
−1.89
1.86
−1.82
−3.11
−0.35
0.24
−1.12
−2.41
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−121.8
−89.5
−15.5
15.1
−47.6
−95.2
·
·
−979.6
−179.4
−232.0
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed